These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 10942942)

  • 1. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
    Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L
    Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942
    [No Abstract]   [Full Text] [Related]  

  • 2. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
    Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
    Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
    Vivanco Martínez JL; López Pérez J; Melero Moreno C; Torres Valdivieso MJ; Palacios López ME; Contra Gómez T; Martín Ramos N; Bernacer Borja M; Gil López C; Valverde Moreno F
    An Esp Pediatr; 1998 Dec; 49(6):603-8. PubMed ID: 9972623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.
    Felice MS; Rossi JG; Gallego MS; Alfaro EM; Zubizarreta PA; Fraquelli LE; Alonso CN; Guitter MR; Scopinaro MJ
    Pediatr Blood Cancer; 2011 Jul; 57(1):47-55. PubMed ID: 21394895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of the reaction to steroids in the treatment of acute lymphoblastic leukemia in children].
    Urasiński T; Peregud-Pogorzelski J; Bartoszewicz L
    Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):360-2. PubMed ID: 1437754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
    Sato Y; Ito R; Saito T; Suto Y; Tateoka N; Onodera N; Ikeda Y; Ito E; Miyano T; Tachibana N
    Rinsho Ketsueki; 1989 Nov; 30(11):1923-30. PubMed ID: 2607611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
    Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
    Kudva GC; Chandy M; Dennison D; Srivastava A; Bhushan V
    Indian J Cancer; 1994 Mar; 31(1):1-7. PubMed ID: 8063329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
    Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
    Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression and poor prognosis in childhood acute lymphoblastic leukemia.
    Hecker S; Sauerbrey A; Volm M
    Anticancer Res; 1994; 14(6B):2759-61. PubMed ID: 7872714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy.
    Moritz B; Eder J; Meister B; Heitger A
    Med Pediatr Oncol; 2001 Feb; 36(2):283-9. PubMed ID: 11452936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [DNA index and proliferative activity of blastic cells in childhood ALL].
    Peregud-Pogorzelski J; Fydryk J; Krygier-Stojałowska A; Urasiński T; Kamieńska E
    Acta Haematol Pol; 1995; 26(1):73-9. PubMed ID: 7747566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.